BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary TB

12 March 2026

BioVersys press release

BioVersys AG announced that the first patient has been dosed in a pulmonary TB Phase 2b clinical trial, evaluating the efficacy, safety and pharmacokinetics of alpibectir-ethionamide (AlpE) in combination with first-line TB drugs.

In this new Phase 2b trial, a portion of the recruited adults with drug-sensitive pulmonary TB will be dosed for 2-months with RZE (rifampicin (R), pyrazinamide (Z) and ethambutol (E)) in combination with AlpE, followed by 18 weeks with RH (rifampicin (R) and isoniazid (H)) alone, to assess efficacy, safety and pharmacokinetics of AlpE. The study is being conducted in six African countries under the European Union’s IMI2 UNITE4TB project, with the Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich as the trial sponsor. Through this Phase 2b TB drug combination trial, BioVersys and its partner GSK are progressing the development of this unique combination and taking the next step in terms of dose finding and potential positioning of AlpE in future TB drug regimens. This trial is expected to read-out by the end of 2027.

Read the full press release here.

Source: BioVersys